Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis

Shock

Volumn 22, Issue 4, 2004, Pages 309-313

  Bozza, Fernando A ^a,b,c   Gomes, Rachel N ^c   Japiassú, André M ^a,b   Soares, Marcio ^d   Castro Faria Neto, Hugo C ^c   Bozza, Patrícia T ^c   Bozza, Marcelo T ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Hospital Espanhol   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Cytokine; IL 6; Markers; MIF; Mortality; Sepsis

Indexed keywords

CYTOKINE; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICAL ILLNESS; DISEASE MARKER; FATALITY; FEMALE; HUMAN; MALE; MORTALITY; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SURVIVAL; TREATMENT INDICATION;

ADULT; AGED; APACHE; AREA UNDER CURVE; BIOLOGICAL MARKERS; BRAZIL; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-6; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SHOCK, SEPTIC;

EID: 8344274437     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000140305.01641.c8     Document Type: Article

References (39)

1. Baugh JA, Bucala R: Macrophage migration inhibitory factor. Crit Care Med 30:S27-S35, 2002.
2. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J: Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 4:449-460, 2002.
3. David JR: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56:72-77, 1966.
4. Bloom BR, Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80-82, 1966.
5. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756-759, 1993.
6. Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895-1902, 1994.
7. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T, Bucala R: An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849-7854, 1996.
8. Herriott MJ, Jiang H, Stewart CA, Fast DJ, Leu RW: Mechanistic differences between migration inhibitory factor (MIF) and IFN-gamma for macrophage activation. MIF and IFN-gamma synergize with lipid A to mediate migration inhibition, but only IFN-gamma induces production of TNF-alpha and nitric oxide. J Immunol 150:4524-4531, 1993.
9. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R: Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33:14144-14155, 1994.
10. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68-71, 1995.
11. Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA, Calandra T, Gemsa D, Donnelly T, Atkins RC, Bucala R: Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 150:235-246, 1997.
12. Calandra T, Spiegel LA, Metz CN, Bucala R: Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of gram-positive bacteria. Proc Natl Acad Sci USA 95:11383-11388, 1998.
13. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR: Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189:341-346, 1999.
14. Makita H, Nishimura M, Miyamoto K, Nakano T, Tanino Y, Hirokawa J, Nishihira J, Kawakami Y: Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 158:573-579, 1998.
15. Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WA, Metz CN, Bruce LJ, Bucala R: Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3:320-323, 1997.
16. Lai KN, Leung JC, Metz CN, Lai FM, Bucala R, Lan HY: Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J Pathol 199: 496-508, 2003.
17. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170, 2000.
18. Roger T, David J, Glauser MP, Calandra T: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414:920-924, 2001.
19. Joshi PC, Poole GV, Sachdev V, Zhou X, Jones Q: Trauma patients with positive cultures have higher levels of circulating macrophage migration inhibitory factor (MIF). Res Commun Mol Pathol Pharmacol 107:13-20, 2000.
20. Gando S, Nishihira J, Kobayashi S, Morimoto Y, Nanzaki S, Kemmotsu O: Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intens Care Med 27:1187-1193, 2001.
21. Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C, Hoeft A, Stuber F: Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 27:1412-1415, 2001.
22. Beishuizen A, Thijs LG, Haanen C, Vermes I: Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 86:2811-2816, 2001.
23. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992.
24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 13:818-829, 1985.
25. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C: Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166:1197-1205, 2002.
26. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34:1084-1093, 2002.
27. Opal SM: Clinical trial design and outcomes in patients with severe sepsis. Shock 20:295-302, 2003.
28. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP: High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 91:23-29, 1991.
29. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771-778, 1993.
30. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356-362, 1992.
31. Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts CJ, Wretlind B: Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 172:296-301, 1995.
32. Vianna RC, Gomes RN, Bozza FA, Amancio RT, Bozza PT, David CM, Castro-Faria-Neto HC: Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 21:115-120, 2004.
33. Turnbull IR, Javadi P, Buchman TG, Hotchkiss RS, Karl IE, Coopersmith CM: Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 21:121-125, 2004.
34. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JÁ: Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467, 2002.
35. Yang S, Zhou M, Chaudry IH, Wang P: Norepinephrine-induced hepatocellular dysfunction in early sepsis is mediated by activation of alpha2-adrenoceptors. Am J Physiol Gastrointest Liver Physiol 281:G1014-G1021, 2001.
36. Bergmann M, Gornikiewicz A, Tamandl D, Exner R, Roth E, Fugger R, Gotzinger P: Sautner T. Continuous therapeutic epinephrine but not norepinephrine prolongs splanchnic IL-6 production in porcine endotoxic shock. Shock 20:575-581, 2003.
37. Pettila V, Hynninen M, Takkunen O, Kuusela P, Valtonen M: Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 28:1220-1225, 2002.
38. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251, 1999.
39. Riedemann NC, Guo RF, Ward PA: Novel strategies for the treatment of sepsis. Nat Med 9:517-524, 2003.